Childhood Cancer and Blood Disorders

Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, Nysom K, van Eijkelenburg N, Ladenstein R, Castellano A, Gerber NU, Marshall LV, Barone G, Rubio-San-Simon A, Ng A, Vaidya S, Gallego S, Makin G, Burke GAA, McCarthy A, Murphy D, Zwaan CM, López-Almaraz R, Jannier S, Thebaud E, Corradini N, Yeomanson D, Howell L, Tweddle DA, Elliott M, Hobin D, Valteau-Couanet D, Schleiermacher G, Chastagner P, Defachelles AS, Brichard B, George S, Chesler L, Laidler J, Firth C, Holt G, Moroz V, Pearson ADJ, Gates S, Wheatley K, Kearns P, Moreno L.
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
J Clin Oncol. 2026 Jan 20;44(3):176-187.
DOI: 10.1200/JCO-25-01868
IF: 43.4

Castelli S, Schulze F, Thole-Kliesch TM, Astrahantseff K, Barone G, Beck-Popovic M, Berlanga P, Corbacioglu S, Fischer M, Gambart M, George SL, Chesler L, Gray JC, Hero B, Künkele A, Flaadt T, Lang P, Lode HN, Molenaar JJ, Schleiermacher G, Rosswog C, Moreno L, Owens C, Rubio-San-Simón A, Schulte JH, Simon T, Tweddle DA, Deubzer HE, Eggert A
New Drug Development, Immunotherapy and Relapse Groups. Current treatment strategies for first relapse of high-risk neuroblastoma.
Eur J Cancer. 2026 Mar 11;236:116254
DOI: 10.1016/j.ejca.2026.116254
IF: 7.1

Chatzimatthaiou, Sotiroula ;Bonifazi, Fedele ;Gimbert, Anna C. ;Colombatti, Raffaella ;Cremonesi, Francesco ;Glenthoj, Andreas ;Mezzalira, Elisabetta ;Stephanou, Coralea ;Traeger-synodinos, Jan ;Antic, Darko ;Durmaz, Burak ;Gavriilaki, Eleni ;Inusa, Baba ;Landi, Annalisa ;Pellegrini, Mariangela ;Basile, Francesca ;Muth, Stephanie ;Cario, Holger ;Katsantoni, Eleni ;Ruhluel, Dilem ;Lederer, Carsten Werner ;Manu-pereira, Maria Del Mar ;Kountouris, Petros
HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
HemaSphere vol. 9,12 e70258. 8 Dec. 2025
DOI: 10.1002/hem3.70258
IF: 14.6

Río P, Zubicaray J, Navarro S, Gálvez E, Sánchez-Domínguez R, Nicoletti E, Sebastián E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yáñez RM, Alberquilla O, Díez B, Fernández-García M, García-García L, Ramírez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, García de Andoin N, López-Almaraz R, Catalá A, Barquinero J, Rodríguez-Perales S, Rao G, Surrallés J, Soulier J, Díaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA;
FANCOLEN-1 gene therapy investigators. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.
Lancet. 2025 Dec 21;404(10471):2584-2592.
DOI: 10.1016/S0140-6736(24)01880-4.
IF: 88.5

Carceller F, Bautista F, Van Tinteren H, Castañeda A, Surun A, Wasti A, Revon-Rivière G, Bergamaschi L, Cortés M, Hladun-Álvaro R, Jiménez I, Giraud C, Millen G, Campbell-Hewson Q, Juan-Ribelles A, Van der Lugt J, Amoroso L, Bertorello N, Hargrave D, Vega-Piris L, Fagioli F, Haupt R, Zwaan CM, Cañete A, Morland B, Ceraulo A, Casanova M, Verschuur A, André N, Aerts I, Doz F, Pearson ADJ, Marshall LV, Vassal G, Kearns P, Geoerger B, Moreno L.
Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study.
Eur J Cancer. 2025 Sep 9;227:115627.
DOI: 10.1016/j.ejca.2025.115627
IF: 7.1